Newest Short Interest Filing: Is Buying Beigene Limited Ads (NASDAQ:BGNE) Here Good Idea?

November 25, 2016 - By Peter Erickson   ·   0 Comments

Newest Short Interest Filing: Is Buying Beigene Limited Ads (NASDAQ:BGNE) Here Good Idea?

The stock of Beigene Limited Ads (NASDAQ:BGNE) registered an increase of 13.47% in short interest. BGNE’s total short interest was 879,300 shares in November as published by FINRA. Its up 13.47% from 774,900 shares, reported previously. With 70,100 shares average volume, it will take short sellers 13 days to cover their BGNE’s short positions. The short interest to Beigene Limited Ads’s float is 7.8%. The stock increased 1.28% or $0.41 during the last trading session, hitting $32.41. About 51,512 shares traded hands. Beigene Ltd (ADR) (NASDAQ:BGNE) has risen 6.99% since April 22, 2016 and is uptrending. It has outperformed by 1.58% the S&P500.

BeiGene, Ltd. is a biopharmaceutical company. The company has a market cap of $1.28 billion. The Firm is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It currently has negative earnings. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

More recent Beigene Ltd (ADR) (NASDAQ:BGNE) news were published by: Marketwatch.com which released: “BeiGene Ltd. ADR” on October 25, 2015. Also Quotes.Wsj.com published the news titled: “DOW JONES, A NEWS CORP COMPANY” on January 31, 2016. Businesswire.com‘s news article titled: “Citi Appointed Depositary Bank for BeiGene, Ltd.’s Sponsored ADR Program” with publication date: February 08, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>